相关实验视频
Updated: Sep 12, 2025

08:16
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
6.8K
细胞异质性在甲状腺癌中的作用:采用孟德尔随机化的多模式分析方法
Yichun Qian1, Wei Chen1, Xinyuan Chen1
1Department of Head and Neck Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, No. 42 Baiziting, Xuanwu District, Nanjing, 210009, Jiangsu, China.
Discover oncology
|August 6, 2025
概括
像AXIN1这样的炎症基因变异与增加甲状腺癌风险有因果关系. 了解这些遗传因素和瘤微环境有助于开发新的风险预测策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺癌的发展受到遗传因素和瘤微环境的影响.
- 炎症基因变异在甲状腺癌风险中的确切作用和瘤生态系统的细胞构成尚未完全理解.
研究的目的:
- 研究炎症蛋白基因与甲状腺癌风险之间的因果关系.
- 描述甲状腺癌微环境中的细胞组成和分化途径.
主要方法:
- 孟德尔随机化 (MR) 分析使用炎症蛋白的遗传变异 (例如,AXIN1,ADA) 来评估对甲状腺癌风险的因果关系.
- 单细胞RNA测序 (scRNA-seq) 用于分析细胞异质性,识别细胞类型,推断甲状腺瘤的分化轨迹.
主要成果:
- 核磁共振分析表明,AXIN1表达与甲状腺癌风险之间存在显著的积极因果关系,而ADA表达则显示出保护作用.
- scRNA-seq确定了六种主要细胞群 (上皮细胞,T细胞,NK细胞,纤维细胞,树突细胞,巨细胞) 和四种独特的细胞状态,具有独特的分子特征.
- 伪素体分析显示,NK细胞和巨细胞在分化早期出现,而上皮细胞和纤维细胞表现出多种发育状态.
结论:
- 炎症性蛋白质基因,特别是AXIN1,表明与甲状腺癌风险的因果关系.
- 这些发现为改善甲状腺癌风险预测和治疗干预提供了潜在的分子标.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
5.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.1K
Cancers Originate from Somatic Mutations in a Single Cell
12.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.8K

